P2RY12 and Stroke: The PIONEER PCI trial466 compared the primary safety outcome and the occurrence of a major adverse cardiovascular event (a composite of death from cardiovascular causes, myocardial infarction, or stroke) between dual therapy with rivaroxaban 15 mg plus P2Y12 inhibitor (n=709) for 12 months and triple therapy with VKA plus DAPT adjusted for 1, 6, or 12 months (n=706).